



Sunday • March 10, 2024

HAPPENING TODAY

🖅 AAD/A Annual **Business Meeting** 8-8:45 a.m. Location: Room 20B

Plenary lineup

8:45-11:30 a.m.

8:45 a.m. **Chair's Welcome** Hensin Tsao, MD, PhD, FAAD

8.50 a m

Clarence S. Livingood, **MD Memorial Award** and Lectureship: Photodermatology: Past, Present, and Future Henry W. Lim, MD, FAAD

9:15 a.m.

President's Address Terrence A. Cronin Jr., MD, FAAD

9:30 a.m.

Lila and Murray Gruber **Memorial Cancer Research** Award and Lectureship: Imatinib as a Paradigm of **Targeted Cancer Therapies** Brian J. Druker, MD

9:55 a.m.

President-Elect Address Seemal R. Desai, MD, FAAD

10:10 a.m.

Marion B. Sulzberger, **MD Memorial Award** and Lectureship: Sensing Inflammation at the Barrier Brian S. Kim, MD, MTR, FAAD

10:35 a.m.

John Kenney Jr., MD Lifetime Achievement Award and Lectureship: Health Equity in Dermatology: What Can I Do? Patricia Treadwell, MD, FAAD

10:55 a.m. Keynote **Speaker** William Shatner



Effective therapies now available for hidradenitis suppurativa.

caring for patients with HS," said

Dr. Naik, who provides specialty

care for patients with HS in the

Suppurativa Clinic, which she

To support dermatologists in

providing up-to-date care to

their HS patients, panelists

presented clinically relevant data

approved therapy secukinumab,

and non-biologic and non-small

on novel therapeutics for HS,

including the recently FDA-

molecule inhibitor therapies

that show promise for HS as

well as pain management and

office-based procedures. They

also highlighted therapies you

can expect to see coming down

the pipeline in the next year or

so, including novel interleukin

(JAK) inhibitors for the treatment

(IL)-17, IL-1, and Janus kinase

Experts weigh in

The session also included

presentations by panelists

of HS.

established in 2016.

Bench to bedside

applications

context of the UCSF Hidradenitis

he biology of hidradenitis suppurativa (HS), also known as acne inversa, is not always understood, which has limited the development of effective therapies for this chronic inflammatory skin condition predominant among women and minoritized patient groups — until now. Recent treatment advancements include novel therapeutics and office-based surgical and laser therapies.


Saturday's session, So33 -Hidradenitis Suppurativa/Acne Inversa (HS/AI): Current Medical and Surgical Management, brought renewed attention to the condition and hope for patients, said session director Haley Naik, MD, FAAD, associate professor of dermatology at the University of California, San Francisco (UCSF) School of Medicine.

"With recent advances in the field, there are now several novel and effective therapies that are either FDA-approved, in the pipeline to approval, or otherwise available to care for this underserved patient population," said Dr. Naik.

Serious and complex

HS can present as deep-seated nodules and abscesses, draining dermal tunnels, and fibrotic scars most commonly in intertriginous areas, such as the axillary, groin, perianal, perineal, and inframammary locations. Dr. Naik and a panel of experts provided an overview of HS epidemiology, etiology, and comorbidities, and the latest advancements in the medical and office-based surgical and laser therapies for HS, including how to access them for your patients and how to ensure that your patients feel confident about trying these treatments.

"Understanding the patient journey, eliciting treatment goals, and helping patients navigate the health care system are keys to



"Understanding the patient journey, eliciting treatment goals, and helping patients navigate the health care system are keys to caring for patients with HS."

– Haley Naik, MD, FAAD

Ra'ed Alhusayen, MD, MSc, FAAD, "Epidemiology and Comorbidities of HS;" Leandra Alicia Barnes, MD, FAAD, "Optimizing the HS Clinic Visit;" John Frew, MBBS, IFAAD, "Pathophysiology of HS;" Daniel Mark Klufas, MD, FAAD, "Office-Based Surgical Procedures for HS;" Tiffany Mayo, MD, FAAD, "Overcoming Barriers to Therapeutic Access;" Robert Micheletti, MD, FAAD, "HS Medical Management With Biologics and Small Molecule Inhibitors;" and Lauren Orenstein, MD, FAAD, "HS Pain

Management." Collectively, panelists discussed tools to access the latest novel treatments for people living with HS, such as secukinumab, and how to effectively use existing HS therapies, including infliximab, ertapenem, and biosimilar drugs.

Get social!

Follow @AADmember on Facebook, Instagram, and X your experiences and colleagues using the official meeting hashtag **#AAD2024**. Look for the giant AAD letters for a fun photo opp and participate in the daily challenges on X and Instagram!

See page 15 for more details.

Attendees also came away with a roadmap for coordinating the care of complex comorbid conditions in collaboration with primary care and specialties including surgery, pain management services, counseling services, rheumatology, and obstetrics and gynecology.

Moving the needle

Although the AAD's Hidradenitis Suppurativa Symposium has been ongoing for over a decade, these recent advancements make it an especially opportune time to put HS on your radar, Dr. Naik said.

"We have never as a specialty or field been better positioned to care for our patients who live with HS than we are today," she said. "As physicians who deeply care for our patients, this is a gratifying moment in which to practice."



Inside

Meet the candidates 3 That worrisome rash: pediatric allergy contact dermatitis 6 Fox Award winners 7 Off label, on point 8 It's personal: treatment for acquired pigmentary disorders 10 Pearls from both sides of the pond 16 Boards and Beyond 16 To serve and protect: skin barrier 17 High-tech hair growth 22

I am modernizing dermatology

M

The business and practice of dermatology never stops evolving... and neither do I. That's why I choose solutions that help prepare me for the challenges of today and set me up for success in the future. Innovations that help ease staffing and scheduling concerns, minimize billing and revenue shortfalls, and simplify patient communication at every step.



Integrated derm-specific EHR + PM + RCM solution* + Analytics + Patient Collaboration

Find us at booth #5129



Get a demo and be entered for a chance to win an Apple Watch Series 9

modmed.com/dermatology · 561.235.7501



*2024 Black Book^{7M} | ©2024 Modernizing Medicine, Inc.

Who will be the future leaders of the Academy?

The Nominating Committee voted to present the following slate of candidates (listed in random order) for the 2024 Academy election of Officers, Directors, and Nominating **Committee Member Representatives** (West Region).

Visit the AAD Election Connection at aad.org/election to learn about this year's candidates and to interact with them on top issues via the online Ask the Candidates forum.

Nominating Committee Member Representatives



MD, FAAD



Lindsay Ackerman,

Hot spot!

Cory Rubin, MD, FAAD

Easily vote using personalized voting link beginning March 9.

President-Elect



MD, FAAD

Board of Directors



MSc, FAAD



MD, PhD, FAAD



Seth L. Matarasso, MD, FAAD

Murad Alam, MD,

FAAD



Alina G. Bridges, DO, FAAD



Glenn D. Goldman, MD, FAAD

Eligible voting members can easily vote using their personalized voting link starting March 9. Watch your email inbox for voting reminders that include this link. Members can access the AAD Election Connection at aad.org/election to view/print the election ballot book and learn more about the candidates.

Nearly 100 firefighters received a skin check and education about cancer in the Sails Pavilion on Saturday. The checks were performed

Firefighter Skin Cancer Checks program, which launches nationally

by 20 volunteer AAD members to kick off the Academy's new

this summer. We even caught a suspected melanoma.







FAAD



Michael G. Wilkerson, MD, FAAD



MPH, FAAD

516

View more meeting coverage at DermWorld **Meeting News** Central



Scan the QR code for instant access to daily articles, photos, and late-breaking research from the Annual Meeting.

aadmeetingnews.org





Larry Green, MD,

Vice President-Elect

FAAD

Andrew F. Alexis, MD, MPH, FAAD

Marc D. Brown, MD,







নিবি

3

Location: Room 31B

S050 – Late-Breaking Research: Session 2 1-4 p.m. Location: Room 20B

S052 – Atopic Dermatitis 1-4 p.m. Location: Room 6B

S053 – Boards Blitz 1-4 p.m. Location: Room 1B





Digginal Control of C



© 2024 Amgen Inc. All rights reserved. 01/24 USA-407-83467

THE ADVENTURE STARTS AT THE OTEZLA BOOTH

If you see a waterfall, you're headed in the right direction

That worrisome rash

Tackling pediatric allergic contact dermatitis ASAP.

Allergic contact dermatitis is estimated to affect

6



TOP TRIGGERS:



Metals Such as nickel and cobalt



Preservatives Such as methylisothiazolinone and formaldehyde



Sudsing agents Such as cocamidopropyl betaine and glucosides



Fragrances



here's good reason to rapidly pursue more answers for managing pediatric cases of allergic contact dermatitis. Currently, there are no treatments for allergic contact dermatitis in children except avoidance.

Allergic contact dermatitis occurs at a high prevalence, according to JiaDe Yu, MD, FAAD, professor of adult and pediatric dermatology at Harvard Medical School in Boston. Dr. Yu, who was the director of Saturday's session, F047 - Considerations in Allergic Contact Dermatitis, said it is estimated to affect about 20% of the world's general population, and nearly 20% of children with atopic dermatitis, making it an

important diagnosis to consider in the clinical setting.

"The goal of our session is to introduce several important concepts, including how to patch test children, what to patch test them to, and finally giving the audience the realization that patch testing in children with atopic dermatitis that is atypical in presentation or response to treatment may yield steroid/ systemic-sparing outcomes," Dr. Yu said.

Top 10 triggers

Part of the session explored the most up-to-date data on the prevalence of contact allergens in children, as published by



the North American Contact Dermatitis Group and other international study groups. Another focus was on the top 10 trending allergens affecting children. According to Dr. Yu, the top allergens in children include metals such as nickel and cobalt, preservatives such as methylisothiazolinone and formaldehyde, sudsing agents such as cocamidopropyl betaine and glucosides, and fragrances.

"These are found everywhere in common day-to-day personal care products, toys, chairs at school, homemade slime, etc.," he said.

Dr. Yu and his researchers are currently studying contact allergens in children, particularly those with atopic dermatitis, to show that children can develop both allergic contact dermatitis and atopic dermatitis. Another area of study, he said, is whether patch testing while on a systemic treatment for atopic dermatitis, such as dupilumab, can still provide accuracy.

Avoidance may be best

Without effective treatment for allergic contact dermatitis, the session explored ways to avoid triggers as well as when to patch test. Patch testing is important in children to detect underlying causes of eczematous rashes that may not look like or respond to typical atopic dermatitis treatments. According to Dr. Yu, patch testing young children requires a special

technique and an extra judicious selection of allergens.

"Not patch testing children could potentially miss cases of superimposed allergic contact dermatitis, placing children unnecessarily on systemic treatments of atopic dermatitis," he said.



Session panelists also provided guidance in the detection of photoallergies in children and their mimickers. Photoallergies in children is an understudied field, Dr. Yu said. The most common causes of photoallergies in children, he said, are chemical sunscreen filters. Physical blockers like zinc and titanium are uncommon causes. Other additives in sunscreens can also cause photoallergies, though phototesting done only at special centers can detect this.

"Mimickers of photoallergy in children are vast and can include allergic contact dermatitis, polymorphous light eruption, juvenile spring eruption, drug photosensitivity, photoirritant dermatitis, or solar urticaria, just to name a few," Dr. Yu said.

Other presenters included Brandon L. Adler, MD, FAAD; Paul Lorenzo Bigliardi, MD, IFAAD; Shaina George; Margo Reeder, MD, FAAD; and Mykayla Sandler.

"Not patch testing children could potentially miss cases of superimposed allergic contact dermatitis, placing children unnecessarily on systemic treatments of atopic dermatitis."

– JiaDe Yu, MD, FAAD

Access approximately 200 sessions from the meeting!

2024 Annual Meeting On-Demand is the perfect way to review sessions you attended or catch ones you missed. You'll get access to the PowerPoint presentations and audio of the selected sessions. New this year, claim CME credit for the sessions you watch on-demand!

Meeting attendees receive an exclusive discount on-site. Visit the AAD Resource Center in the Exhibit Hall, Booth 739.



Fox Award: The future of dermatology recognized

The Residents and Fellows Symposium was held Saturday, during the 2024 AAD Annual Meeting in San Diego, led by Cory A. Dunnick, MD, FAAD. Faculty judges selected individuals who presented the most outstanding papers in laboratory and clinical research. The winners of this year's prestigious Everett C. Fox Memorial Award are listed below.



Congratulations to all who participated in the 2024 Resident and Fellows Symposium!

Basic Science Category

Winner name: Kevin Severson, MD **Title:** Clinical, Pathological, and Molecular Changes of Intermediate-to-High Risk Cutaneous Squamous Cell Carcinoma (cSCC)

Winner name: Amy Petty, MD

Title: Single Cell RNA Sequencing Reveals Complex Keratinocyte Landscape in Acute and Chronic Cutaneous Graft-versus-Host Disease

Winner name: Conor Broderick

Title: Associations Between the Early-Life Skin Microbiome And Hygiene-Related Exposures, Including Infant Skin Care

Winner name: Isara Yenyuwadee, MD

Title: The Efficacy of Nail Gutter Method for Epidermal Growth Factor Receptor Inhibitors-Induced Nail Changes: A Randomized, Single-Blinded, Intra-Individual Study

Clinical Category

Winner name: Kyle Lauk, MD

Title: Sexual Dysfunction With 5-Alpha-Reductase Inhibitor Therapy for Androgenetic Alopecia: A Global, Propensity Score Matched, Retrospective Cohort Study

Winner name: João Nuno Soares

Title: Decoding β-Lactam Cross-Reactivity: Longitudinal Skin Testing From 2015-2022

Interested in new clinical research for psoriasis?

Visit booth #5115 to learn about the Latitude Psoriasis Clinical Trials



The investigational product being studied in the Latitude Porsiasis Clinical Trials has not been approved by any regulatory body nor has the safety or effectiveness been established There is no guarantee that the product will receive regulatory approval and become commercially available for the use(s) being investigated. VV-MEDMAT-96325 [December 2023 © 2024 Takeda Pharmaceuticals U.S.A., Inc., All rights reserved. TAKEDA and the TAKEDA logo are registered trademarks of Takeda Pharmaceutical Company Limited. For Halthcare Professionals only.

RESIDENT JEOPARDY

New champs announced



Winning team: Einstein Bros. Albert Einstein School of Medicine Jose Jaller, MD Suraj Reddy Muddasani, MD



PRODUCT SHOWCASE

Sanofi's Dermatology Pipeline Clinical Trials

Learn more here:



Off label, on point

Spironolactone can be an effective treatment for patients with acne.



Emmy Graber, MBA, MD, FAAD, founder and director of the Dermatology Institute of Boston

S pironolactone is primarily used for the treatment of heart failure, high blood pressure, or hypokalemia but more than a few dermatologists know that it can also be a secret weapon for treating acne in women.

Emmy Graber, MBA, MD, FAAD, founder and director of the Dermatology Institute of Boston, said that in spite of it being used for acne treatment for years, some dermatologists remain a little uncertain about using it today.

"It has FDA approval for other indications, but not for treating acne, and for that reason, some dermatologists are a little hesitant to use it for acne because it is an off-label use," she said. The use of spironolactone was explored by Dr. Graber and other presenters, including Hilary Baldwin, MD, FAAD, Julie Claire Harper, MD, FAAD, and Bethanee Jean Schlosser, MD, PhD, FAAD, in Friday's session, Fo21 – Practical Guidelines for Using Spironolactone in Acne Patients.

Pinpointing the patient

One of the keys to effectively using the drug, Dr. Graber explained, is knowing who will benefit the most. For example, she said spironolactone is primarily used in women because of its potential side effects (such as gynecomastia) in men. But there are other factors to consider in deciding who is — and isn't — a good candidate.

"You have to look at the age of the patient when we might start treatment," Dr. Graber said. "It also depends on what type of acne they have. We used to think that patients who were good candidates had primarily lower face or jawline acne, but that's not necessarily the case anymore."

Dr. Graber said dermatologists also must know when it is appropriate to do a lab workup in patients who may benefit from spironolactone treatment.

"Do we think that everyone whose acne



flares up around the time of the menstrual cycle needs a hormonal (lab) workup for that acne?" she asked. "Probably not, but there are some telltale signs to look for, such as hirsutism, a deepening of the voice, and irregular periods, which may warrant a laboratory workup."

Consider the side effects

As with any drug, there are potential side effects to consider with spironolactone, such as irregular menstrual cycles and the potential for hyperkalemia.

Dr. Graber said there has long been concern over the possibility of breast cancer as well.

"Some physicians are leery of putting patients on spironolactone because of breast cancer concerns, but this is not supported by scientific studies," she said. Ultimately, Dr. Graber said it is up to dermatologists to decide if spironolactone is right for them and for their patients. But whether they use it or not, they should at least be aware of its potential and its benefits to the medical community.

"It is of particular interest to

dermatologists because, although it is off-label, it can be a very successful treatment for acne," she said. "In this era of antibiotic stewardship, we're using

antibiotics more selectively these days, so we want alternatives, and this is a non-antibiotic alternative that dermatologists should consider. It's been proven to be an effective drug for treating acne."

PHOTO GALLERY



Scan the QR code to view the AAD Annual Meeting Photo Gallery aadmeetingnews.org/photo-gallery

Embrace the future of aesthetic skincare!



Skin Brightening System

SOLIE

Booth 3327

lt's personal

Expansive treatment regimen available for acquired pigmentary disorders.

ew disease phenotypes are as visually compelling, or as challenging to treat, as chronic hyperpigmentation. But now it's getting personal. The increase in the treatment of acquired pigmentary disorders — approximately 1.5 million dermatology visits annually in the U.S. — has provided a wealth of background information and new opportunities to personalize a corrective regimen.

That was welcome news for dermatologists who attended Friday's session, F022 – Fifty Shades of Brown: Science, Symptoms, and Strategies for Acquired Pigmentary Disorders. Sandy Sharon Tsao, MD, FAAD, who led the session, credits rapid advances in molecular and biologic therapeutics and breakthroughs in device technology with bringing hope to patients. Dr. Tsao is an assistant professor of dermatology at Harvard Medical School in Boston.

"Every individual has a unique ethnic background, history of environmental exposures, history of response to injuries, and family history. The personalization in diagnosing dyschromias is in determining these unique factors to help tailor your treatment plan to that individual," Dr. Tsao said.

Getting it right, globally

Acquired pigmentary disorders, such as post-inflammatory hyperpigmentation and melasma, represent some of the most common cutaneous concerns globally. For many years, according to session presenter, Arianne Shadi Kourosh, MD, MPH, FAAD, associate professor of dermatology at Harvard Medical School, the treatment approach focused on targeting the tyrosinase enzyme in the pathway of melanin production. In recent years, however, researchers are looking at other pathways, including the interaction of melanocytes with keratinocytes.

"It is also important that other environmental triggers and exacerbating factors beyond ultraviolet radiation and their role in worsening hyperpigmentation have become a greater focus of research and public education, such as visible light, heat or infrared radiation, and pollution." Dr. Kourosh said. "For years, I have been concerned and lecturing about the role of pollution in dyschromia and skin aging, especially in caring for people who traveled to our clinic from countries in the world with high pollution levels. Now with rising air pollution in certain regions of the U.S. (hitting peak levels in the northeast in 2023), it could be an increasingly relevant trigger for patients."

Proper diagnosis is the first step toward treating the disorder. And that requires

What's right for your patient?

Current and future medical, surgical, or combination treatment strategies have evolved.

Current treatment strategies include preventative measures, topical medications, oral medications, peeling agents, resurfacing procedures, PRP, and microneedling technologies.

More recently, the

use of oral antioxidants has come into play as preventative agents. These include vitamin E, polypodium leucotomos, niacinamide, pyconogenol, grapeseed extract, and glutathione.

·六· SPF

Preventative measures including recognizing the role that visible and ultraviolet light play in exacerbating dyschromia is vital to minimizing further development of pigmentary changes. Maximizing sun protective measures is critical, including daily broad-spectrum tinted sunscreen use with physical blocking agents, like titanium dioxide, zinc oxide, and iron oxide. Sun-protective clothing is paramount.

a thorough patient history, Dr. Tsao said. Dermatologists should be asking patients about the duration of the pigmentary changes, exploring whether there is a known underlying causal etiology for the changes, if injury is an isolated or ongoing event, treatment and response history, family history, a physical exam with attention to the location of the pigmentary changes, and ethnicity.

"Consideration of ethnic background comes into play when considering specific medical dyschromia, including ashy dermatosis, lichen planopilaris postinflammatory hyperpigmentation, and melasma," Dr. Tsao said. "These conditions present more commonly in patients of specific ethnic backgrounds, requiring a broader consideration for underlying diagnoses."

Risk assessment

Individuals with darker skin phototypes may be at higher risk of exacerbating their dyschromia when exposed to ultraviolet or visible light as well as excessive heat, according to Dr. Tsao. Patients with darker skin phototypes respond more vigorously to many treatment options, with a higher risk of post-inflammatory hyperpigmentation and scar formation, which must be considered when determining a treatment plan.

"Understanding how to determine the risk/benefit profile, having the correct treatment agents and devices in your office, and how to provide the appropriate treatments is critical for safe and effective outcomes," Dr. Tsao said.

New and breakthrough treatment

Currently, a combination of topical and oral medical therapies as well as laser treatments and chemical peels are used with varied efficacy depending on the causes and levels of depth in the skin affected in the dyschromia, according to Dr. Kourosh. With laser treatments and chemical peels, the heat or irritation caused by some of these procedural treatments (if they are not in the hands of a highly skilled dermatologist) can worsen the problem.

"This is especially concerning for my patients with darker skin types who are more vulnerable to hyperpigmentation from these treatments and who have suffered and been burned in some cases by practitioners who were not sufficiently trained in the care of their skin. New treatments are in the pipeline and more are needed," Dr. Kourosh said.

Dr. Tsao offered more on recent scientific breakthroughs in the understanding of normal melanocyte biology and abnormal

The emotional toll

Dr. Kourosh reminds dermatologists of the emotional toll the disorder takes on patients as well as the need for public health education on the problems that arise from cultural pressures surrounding colorism and the unsafe skin bleaching practices in our society.

.

"I have developed a deep appreciation and empathy for struggles these patients face, feeling disfigured especially in the challenging cases that persist despite all of our current therapies," she said.

"We need to improve treatments for pigmentary problems, while also improving medical education and public education to protect patients from misinformation and threats to the health of their skin and well-being, and promote a more diverse ideal of beauty and healthy skin."

Making an effective, tailored treatment plan for each unique patient requires:

- Taking a thorough history
 Ensuring a correct diagnosis for the underlying dyschromia
- Evaluating past treatment responses
- Understanding the risk profile of each treatment
- Identifying triggers

Identifying triggers is key

Without removal of triggers, the problem could perpetuate and even the best therapies could be limited in

their impact. Addressing triggers for a

person's hyperpigmentation is critical

to tailoring the right treatment plan.

pigment physiology have been key to treatment regimens, including advances in the understanding of abnormal pigment physiology. This focuses on the effects of UV as well as visible light-induced skin injury, and the influence of inflammation and skin barrier dysfunction.

These changes include increased expression of VEGF, increased dermal vessels, basement membrane damage, increased WNT expression, increased mast cell production, increased fibroblast senescence, oxidative stress, and increased estrogen and progesterone receptors. In the future, Dr. Tsao said, a better understanding of the role of these changes will allow for the development of more targeted therapies.





Sandy Sharon Tsao, MD, FAAD, assistant professor of dermatology at Harvard Medical School in Boston

Combination treatments

measures, maximizing topical

treatments such as peels and

laser/energy-based devices will

maximize treatment outcomes.

A thorough understanding

of the interactions of combination therapies is

necessary to minimize

potential side effects.

Specifically, combining preventative

therapies, and using conservative


Arianne Shadi Kourosh, MD, MPH, FAAD, associate professor of dermatology at Harvard Medical School



When your patients are **EVERYTHING**, your commitment stops at **NOTHING**



© 2024 AbbVie. All rights reserved. SKYRIZI® and its design are registered trademarks of AbbVie Biotechnology Ltd. US-SKZD-240079 February 2024



Exhibitor Listing

123 – D

3Gen, Inc./DermLite
5CC (5-Continent-Congress)
AAD Industry Product Theater 1 3347
AAD Industry Product Theater 2 2947
AAD Resource Center739
AAD Space Selection Office 3147, 3649
AbbVie
ABISA 2128
Acclaro Medical
Accurate Manufacturing, Inc 5439
AccuTec Inc
Ace Medical Industry Co, LTD 958
ACELYRIN, INC
Acuderm
Advalight
Advanced Dermatology &
Cosmetic Surgery4223
Aeon Biotherapeutics Corp4255
Aerolase
Aesthetic Guide, The
AIM Medical Inc
AIM Medical Inc
AIM Medical Inc
AIM Medical Inc1758Allergan Aesthetics1639, 1811Alletess, Inc.4749
AIM Medical Inc1758Allergan Aesthetics1639, 1811Alletess, Inc.4749ALMIRALL2917
AIM Medical Inc

American Society for

American Society for
Dermatologic Surgery
Amgen, Inc2439
AMLo Biosciences4847
AMP Medical Products, LLC5310
AnteAGE MD by Cellese
APDerm1245
Aqua Dermatology
Aquavit
Arcutis Biotherapeutics, Inc
argenx
ASTERASYS Co LTD
Avantik
Aven, Inc
Avita Medical2512
Balassa Laboratories, Inc
Bank of America Practice Solutions 742
Barnet Products5446
BDSC Company
Beiersdorf, Inc
Beijing HUEFUL Technology Co., LTD .752
Beijing Syntech Laser Co., Ltd3928
Belle.ai
Benefis Health System 5442
Benev Company Inc
Biofrontera, Inc
Biogened S.A
Boehringer Ingelheim
Pharmaceuticals, Inc 3017, 4017, 5353

Data current as of Feb. 23, 2024. Please use the AAD Meeting App **aad.org/mobile** for the most up-to-date exhibitor list.

Bristol-Myers Squibb939, 2130
Brymill Cryogenic Systems
Burton Medical, LLC
Burt's Bees
Caliber Imaging & Diagnostics3439
Candela
Canfield Scientific
Cantabria Labs
CareCredit3517
Casio America, Inc
Castle Biosciences1419
Celldex Therapeutics
Chemistry Rx
Chemotechnique Diagnostics/
Dormer Laboratories
Chiesi US, Inc956
Chowis Co, LTD
CHUNGWOO Co., Ltd1010
Clinical Resolution Lab, Inc 1257
Clinique1325
Clix Therapy
CLN Skin Care (TopMD Skin Care) 4946
Cobalt Medical Supply, Inc
COLA Inc
Collagen P.I.N
CoNCERT Pharmaceuticals Inc 717
Coous Global Co., Ltd
Coronis Health
Cortex Technology Aps

CosmeticRx
CP Skin Health Group
CPMT Laser
Crown Laboratories, Inc
CryoProbe
Cutera
Daavlin
DefenAge
DEKA M.E.L.A. srl
Delasco
Derm Care Billing Consultants 2928
Derma Made LLC
Dermaceutic Laboratoire
Dermadry Laboratories Inc5114
DermapenWorld
DermaSensor Inc5207
Dermatology Foundation
Dermatology Specialists, The 2555
Dermatology Times
Dermavant Sciences, Inc
Dermax Co., Ltd
DermCare Management
Dermogalenic Experts US LLC 5427
Dermpath Diagnostics
DermQBank
DermTech
Designs for Vision, Inc
DiamondTome/Altair Instruments 1015
Dino-Lite



|--|

Earned Wealth756
eClinicalWorks
Edesa Biotech, Inc
Ellis Instruments
Elsevier
Eltraderm Skin Care
EMK Medical
EPI/Alpha-Stim
Epicutis Skin Care2761
Epionce
Epiphany Dermatology4850

and Venereology
Evolus, Inc
EZDerm, LLC
Fabletics Scrubs
Fagron Genomics US
Ferndale Healthcare, Inc
FFF Enterprises
FineMec Co, Ltd
Focus Medical5343
Forefront Dermatology
Fotofinder Systems, Inc
Fotona Lasers
Foundation for Research & Education
in Dermatology

GALDA: Gay & Lesbian Dermatology Hayden Medical Instruments 4332

Hill Dermaceuticals, Inc
Hironic Co., LTD
HK Surgical
Honeydew
Honeywell
HST Tax Advisory Group, LLL 4747
Hyaestic Skincare (La Solae, Inc.) 4247
Hydrafacial
I.E. Natural
Ibero Latin American Collage of
Dermatology/CILAD
ICD 2025, International Congress of
Dermatology
ILOODA Co., Ltd
Image Skincare
ImageBloom
Incyte Corporation 4513, 4907
see EXHIBITOR LISTING page 14

1 5

Sky

abbvie

When your patients are **EVERYTHING**, your commitment stops at **NOTHING**

© 2024 AbbVie. All rights reserved. SKYRIZI® and its design are registered trademarks of AbbVie Biotechnology Ltd. US-SKZD-240080 February 2024

EXHIBITOR LISTING

continued from page 13

Infinity Massage Chairs
Inga Ellzey Billing Companies746
InMode
Innovaderm Research
Innovative Optics Laser
Eye Protection
InStep Health
Integrated Dermatology Group 3225
International Society of Dermatology 5417
IntraOp Medical Corporation3549
ISDIN

$\mathbf{J} - \mathbf{N}$

JAMA Network, The
JDD, Medscape, and SanovaWorks 3132
Johnson & Johnson 1627, 1739
Journal of Clinical and Aesthetic
Dermatology
Jubilee International
Biomedical Co, LTD5155
Kaiser Permanente
Kernel Medical
KL Global Co, LTD2117
Krystal Biotech
LASEROPTEK Co., Ltd729
Laservision4322
LC Cell
LearnSkin
Leaseir
LedgerHealth
LEO Pharma Inc4525
Level Ex5431
Lightfective LTD
Liine
Lilly US, LLC



A Taste of AAD Innovation Academy

10 a.m.-1 p.m. | Friday-Sunday AAD Resource Center

Something is brewing this summer in Seattle! Grab a coffee, learn more about the educational meeting of the summer, and enter for a chance to win FREE registration!

Locks of Love, Inc
LocumTenens.com
L'Oreal Dermatological Beauty 4339
Lumenis
LUMISQUE
LUTRONIC
MAD Skincare
McGraw Hill
MD Charts
MD Cosmetica
mdceuticals
MDedge/Dermatology5255
Medi Lazer
Medicol US
MediLoupes
Medjet
MEDWEB 1239
Mesoestetic SL
MetaOptima Technology Inc1723
Microsurgery Instruments, Inc 2657
Mid Florida Dermatology
& Plastic Surgery
Midmark Corporation
Mimedx Group, Inc
Mindera Health959
MMP Capital1721
Modernizing Medicine, Inc
MTI, Inc
MTS US957
MyDermRecruiter/MyMDRecruiter4755
NL D

N – R

Nanjing Bestview Laser S&T Co. Ltd.....

Marijing Destview Laser
S&T Co, Ltd
NAOS/Laboratoire Bioderma2149
National Eczema Association 3121
National Psoriasis Foundation1110
Neogen5440
NeoGenesis Inc
NeoStrata Company, Inc
Neutrogena2511
NewBeauty714
Newmedical Technology, Inc 1319
NEWPONG CO., LTD
Nextech
NextPatient, Inc
No72121
NoIR LaserShield
Northwestern Medicine5153
Novartis Pharmaceuticals
Novartis Pharmaceuticals Corporation
Novartis Pharmaceuticals
Novartis Pharmaceuticals Corporation

Patient Recruiting Agency, The1338
PatientPoint2510
Person & Covey
Pfizer Inc
Pierre Fabre US2139
Pinnicle Dermatology5325
Platinum Dermatology Partners 4851
PNC Bank
Powered by MRP
PPD955
Practical Dermatology
PracticeLink
Precise Bioscience859
Primus Pharmaceuticals, Inc 4352
Priovant Therapeutics
PRIVI By PatientFi
Procter & Gamble
Promptly Patient Experience Suite 5250
• •
PSI/Vanicream Skin Care
PSI/Vanicream Skin Care.1511Quanta System SPA3039Quantificare2650Quintessence Skin Science5139RAPT Therapeutics3718
PSI/Vanicream Skin Care.1511Quanta System SPA3039Quantificare2650Quintessence Skin Science.5139RAPT Therapeutics3718Regen Lab1945
PSI/Vanicream Skin Care1511Quanta System SPA.3039Quantificare.2650Quintessence Skin Science.5139RAPT Therapeutics.3718Regen Lab.1945Regeneron (LIBTAYO).4729
PSI/Vanicream Skin Care.1511Quanta System SPA3039Quantificare2650Quintessence Skin Science.5139RAPT Therapeutics.3718Regen Lab1945Regeneron (LIBTAYO).4729Regeneron Sanofi.4919
PSI/Vanicream Skin Care.1511Quanta System SPA3039Quantificare2650Quintessence Skin Science5139RAPT Therapeutics3718Regen Lab1945Regeneron (LIBTAYO)4729Regeneron Sanofi4919Replimune2922
PSI/Vanicream Skin Care.1511Quanta System SPA3039Quantificare2650Quintessence Skin Science.5139RAPT Therapeutics3718Regen Lab1945Regeneron (LIBTAYO)4729Regeneron Sanofi4919Replimune2922Replior AB718
PSI/Vanicream Skin Care.1511Quanta System SPA3039Quantificare2650Quintessence Skin Science.5139RAPT Therapeutics3718Regen Lab1945Regeneron (LIBTAYO)4729Regeneron Sanofi4919Replimune2922Replior AB718Revance Therapeutics, Inc.1241
PSI/Vanicream Skin Care.1511Quanta System SPA3039Quantificare2650Quintessence Skin Science5139RAPT Therapeutics3718Regen Lab1945Regeneron (LIBTAYO)4729Replimune2922Replior AB718Revance Therapeutics, Inc.1241Revision Skincare4129
PSI/Vanicream Skin Care.1511Quanta System SPA3039Quantificare2650Quintessence Skin Science.5139RAPT Therapeutics3718Regen Lab1945Regeneron (LIBTAYO)4729Replimune2922Replior AB718Revance Therapeutics, Inc.1241Revision Skincare4129RoC Skincare5107
PSI/Vanicream Skin Care.1511Quanta System SPA3039Quantificare2650Quintessence Skin Science.5139RAPT Therapeutics3718Regen Lab1945Regeneron (LIBTAYO)4729Replimune2922Replior AB718Revance Therapeutics, Inc.1241Revision Skincare4129RoC Skincare5107Rose Micro Solutions3433
PSI/Vanicream Skin Care.1511Quanta System SPA3039Quantificare2650Quintessence Skin Science.5139RAPT Therapeutics3718Regen Lab1945Regeneron (LIBTAYO)4729Replimune2922Replior AB718Revance Therapeutics, Inc.1241Revision Skincare4129RoC Skincare5107

S – V

Saffron Solution, the
San Diego Academy of
Regenerative Therapies 5438
Sandoz Inc
Sanofi
Schweiger Dermatology Group 3727
SciBase
Sciton
Sensus Healthcare
Senté4346
Sesderma
SGS North America
Shanghai Bele Medical
Technology Co, Ltd
Shanghai May Skin Information
Technology Co., Ltd
Shantel Medical Supply1330
shenb Co., Ltd
Shenzhen GSD Tech Co., Ltd 710
SILAB Inc1645
SIV Care
Skin & Aesthetic Centers924
Skin Cancer Foundation, The
Skincare Junkie5455
SkinCeuticals1154
SkinCure Oncology

Skinuva	. 5448
SkylineDx US, Inc	. 3222
Skymedic	. 4350
Slinph Technologies Co., LTD	. 5447
SmartPractice	. 3933
SNJ Co., Ltd	. 5013
Society of Dermatology	
Physician Assistants	. 1112
Sofwave Medical	. 2855
Solumbra by Sun Precautions	. 2829
Solutions Maven Consulting	856
Sonic Healthcare US,	
Dermatopathology	
Sonoma Pharmaceuticals	
Specialty Consulting Services	
Springer Nature	. 2056
SSM Health	. 5241
Sterimedix Ltd	. 2661
Strata Skin Sciences	. 3033
StrataDx	. 4751
Sun Pharma	. 4039
SurgiTel/General Scientific Corp	. 5243
Swift US	716
Sylton Inc	. 2455
Symbio LLC	. 3117
Takeda Pharmaceuticals	. 5115
Tentech Inc	722
TFS HealthScience	. 4320
Tiemann-Bernsco	. 4239
Timeline Nutrition	. 2856
TiZO Skin	. 1729
TKL Research	
Topix Pharmaceuticals, Inc.	
Toskani SL	
Trautec Medical Technology Co. Ltd.	
U.S. Bank	
U.S. Dermatology Partners	
UCB, Inc	
Unilever	
Univa Skincare	
Venus Concept US Inc	
VERRICA.	
Veterans Health Administration	
Viol Co., Ltd	
VisualDx	
Vital Interaction	
VYDENCE Medical	. 2124

W – **Z**

Waldmann Lighting5340
Wallaroo Hat Company1456
WaterWipes
WCD 2027 GUADALAJARA5451
Wellbel Inc
Wingderm Electro-Optics Ltd 3956
WON TECH CO., LTD
World Wide Wolf OU
Xstrahl, Inc
Young Pharmaceuticals, Inc3327
Zero Gravity
Zimmer MedizinSystems
ZO Skin Health

0

AAD2024

Follow @AADmember to win big at Annual Meeting!

What could be better than being in San Diego with all your favorite colleagues? Winning daily giveaways, of course! The @AADmember accounts are hosting new **social media challenges each day of the 2024 AAD Annual Meeting**, from Friday, March 8, until Monday, March 11.

ach day, a post will be shared on Instagram and X (formerly Twitter) that will ask attendees to participate in a new type of challenge. One randomly selected winner will be chosen on each platform to receive a daily giveaway. Prizes will include everything from \$100 gift cards to registration discounts for future AAD meetings. Attendees are encouraged to participate on both platforms to double down on the fun and increase their chances of winning. In addition to offering sizzling prizes, the @AADmember accounts will also be sharing tons of photos and updates about the meeting that you won't want to miss. Be sure to include the official meeting hashtag **#AAD2024** in all your posts to see if your content gets reshared by the AAD! •

For more information, see the official rules and regulations online at aadmeetingnews.org/22886745 or direct message @AADmember on X (formerly Twitter) or Instagram.



15

Navigate the 2024 AAD Annual Meeting from your mobile device!

aad.org/mobile

- Session schedules
- Exhibitor information
- CME
- Session evaluations

A new view of care

When patients reach for everyday care, it's our iconic brands they can trust.

Discover science-backed, care-forward solutions at kenvue.com.



Kenvue





Pearls from both sides of the pond

American and European dermatologists share news on upcoming treatments.



Jeffrey Callen, MD, FAAD, FACP, MACR, professor of medicine and chief of the division of dermatology at the University of Louisville School of Medicine in Kentucky



S059 – The Best of American and European Dermatology 1-4 p.m. | Monday, March 11 Location: Room 6F

HAPPENING TODAY



Morgan Murphrey, MD, MS



Pustular psoriasis is a rare, but serious condition. The good news for dermatologists and their patients is that there are at least two new treatments in the pipeline for pustular psoriasis and other conditions, which may change the way they are managed in the near future.

Jeffrey Callen, MD, FAAD, FACP, MACR, professor of medicine and chief of the division of dermatology at the University of Louisville School of Medicine in Kentucky, said intravenous spesolimab has been approved as a treatment for generalized pustular psoriasis, but it may have even more uses than that. Dr. Callen is the director of Monday's session, So59 – The Best of American and

European Dermatology. "It might eventually be approved as an SQ injection for pustular psoriasis of the palms and soles," Dr. Callen said.

Shared concerns

Other treatments currently being studied include bimekizumab for pustular psoriasis of the palms and soles, nemolizumab for prurigo nodularis, dupilumab for bullous pemphigoid, and mogamulizimab for cutaneous T-cell lymphoma.

The session will also feature a discussion of these treatments and others for multiple conditions, including:

- Blistering diseases
- Chronic urticaria
- Cutaneous T-cell lymphoma
- Hidradenitis
- Itching

 Pustular psoriasis Dr. Callen, working with Michel
 F. Gilliet, MD, the European
 Academy of Dermatology and
 Venereology (EADV) representative, said these topics were selected
 because they are relevant in both
 Europe and the United States.

"But our approaches to evaluation and management

might differ," Dr. Callen said. "There are excellent researchers on both sides of the Atlantic, and we specifically selected these topics as they have new options for therapy that are currently approved or will likely be approved in the near future."

A good fit

Dr. Callen said the AAD has always worked closely with its European counterpart, the EADV, to facilitate the exchange of ideas and research between European and American dermatologists. In fact, that partnership dates back to the formation of the EADV in 1987.

"When [the EADV] was formed, it based its annual meeting format largely on the use of the format of the AAD's Annual Meeting," Dr. Callen said.

In the spirit of cooperation, Dr. Callen said the AAD suggested having a joint session with the two organizations at each other's meetings to better help each association's members understand what was going on across the pond and gain new perspectives on various conditions they were seeing.

"Initially, the AAD session was held during the AAD's summer meeting, but in the last five or so years, the AAD session was moved to the Annual Meeting," Dr. Callen said. "Each organization has a member or committee that suggests three speakers annually for each session after assessing what appears to be the hot topics."

Other topics and speakers at tomorrow's globally inspired session include a lecture on chronic spontaneous urticaria; pruritus by Shawn Kwatra, MD, FAAD; hidradenitis suppurativa by Robert Micheletti, MD, FAAD; a presentation on cutaneous T-cell lymphoma; immunobullous diseases by John Joseph Zone, MD, FAAD; and pustular psoriasis by Jonathan Barker, MD. •

Help with your boards and so much more

Boards and Beyond returns for exam prep and career guidance.

eady for what's beyond residency? Take the time to prepare and learn from others during Sunday's session, Fo84 – Boards and Beyond. The session was so popular in 2023, it's returning for the 2024 AAD Annual Meeting.

Morgan Murphrey, MD, MS, will lead a panel of speakers who have forged unique paths in dermatology and are poised to share practical insights. Speakers represent dermatology in academics, private practice, and more. These are individuals who know that most residents and early-career dermatologists often report feeling inadequately prepared for the nondermatologic aspects of medical practice, Dr. Murphrey said.

"The focus of dermatology residency training is understanding the skin, which is a large task in and of itself. Residents typically work in academic settings, where clinics have extra time built in for learning and discussion. There is typically additional time set aside for didactics or research pursuits," she said. "However, residents do not typically experience the business or administrative side of dermatology."

Feeling unprepared

Some residents, for example, do not have exposure to coding and reimbursement. And because residency is typically associated with a university system, many residents have little experience with other practice settings, such as private practice. These factors result in residents and early-career dermatologists who may not have adequate preparation for the non-academic aspects of medical practice, Dr. Murphrey said.

This session will briefly review the style and structure of the board exam, as well as relevant post-residency requirements (i.e., maintenance of certification requirements).

Participants will have an opportunity for a panel-like discussion with the speakers during the last 20 minutes of the session.

Getting the basics

The session is designed to prepare residents for the format of the American Board of Dermatology Board Examination, explore career and alternative career paths in dermatology, and provide tips and tricks for considering post-residency plans and early-career advice. "Dermatology Board Examination is a day-long exam, which can be taken at a testing center or online, similar to the CORE exams. The test is broken into four blocks of 50 questions. Each block is allotted 94 minutes, and there are breaks during the exam. The questions are multiple choice," Dr. Murphrey said.

Additionally, she said postresidency certification is done through the CertLink program. Each quarter, residents receive six core dermatology questions, and three elective questions based on the topic of their choosing. They also receive four article-based questions, typically based on two articles. Test-takers are given 10 minutes per question, and can reattempt incorrect questions in subsequent quarters, Dr. Murphrey said. This differs from the older re-certification exam, which was required every 10 years.

Where will your career take you?

Residents and early-career dermatologists have employment choices in many diverse areas. Some professionals may be more interested and better suited in private practice or academics, where others migrate to serving patients in rural areas.

"For many dermatologists, there are opportunities to find a 'niche' or further area of interest, and build their practice around that specifically," Dr. Murphrey said. "For example, some dermatologists focus on hair and hair loss, others on pediatric patients, oncodermatology, melanoma, and pigmented lesions. Some dermatologists primarily practice in a research setting, and others work in industry...the list goes on. Our session will aim to give you a better sense of the various avenues of dermatology that can be explored."

Ultimately, Dr. Murphrey said, the session's goal is to offer a roadmap for those who are approaching their final training examination. It is meant to help residents and early-career dermatologists who are seeking inspiration and advice about their dermatology journey.

"As a dermatology resident or fellow, the post-training career hunt can be daunting. Entering our own paths may feel overwhelming. The goal of this session is to share experiences and offer insight for those who are considering how best to approach their future career," she said.

To serve and protect

Healthy skin barrier is essential in the fight against disease.

kin. It's not only the body's largest organ, but it also serves as an important barrier to infection and disease. Protecting that barrier from damage and disruption requires a keen awareness of a multitude of molecular and immunological signaling pathways.

According to Jack L. Arbiser, MD, PhD, FAAD, a dermatologist with Metroderm/ United Derm Partners in Atlanta, careful attention to maintaining the skin's barrier function can guard against specific skin conditions such as atopic dermatitis, psoriasis, or other related issues. Dr. Arbiser unraveled the complexities of the skin barrier — the human shield against disease — during yesterday's session, So39 – Understanding the Skin Barrier.

"The human body is constantly surrounded by a mixture of beneficial and pathogenic bacteria, fungi, and viruses. Given the opportunity, the bacteria will try to invade the body and reach the blood stream," Dr. Arbiser said. "The skin barrier is both a physical barrier, like a suit of armor, and a chemical barrier. The chemical barrier signals immediately that the barrier has been breached and starts beneficial inflammation. In normal skin, inflammation is decreased when the threat is gone."

Barrier breach

Research has shown how disruption of the skin barrier can lead to inflammatory disorders, and how an intact skin barrier results in resolution of inflammation, he said. A healthy skin barrier includes proper maintenance of the acid mantle and appropriate levels of ceramides.

"Three factors are required for barrier



Jack L. Arbiser, MD, PhD, FAAD, dermatologist with Metroderm/ United Derm Partners in Atlanta

function," Dr. Arbiser said. "The first is extracellular acid, which decreases inflammation as well as kills pathogenic staph and strep. Mitochondria are required for optimal production of skin structural proteins and antimicrobial peptides. Ceramides are the waxy lipids that waterproof the skin barrier and can be rapidly converted to proinflammatory sphingosine-I phosphate to signal inflammation." Although acute inflammation is

necessary to fight off immediate threats, "sometimes the body does not turn off the inflammation or is signaling that it is being attacked when it is not," Dr. Arbiser said.

"This underlies chronic inflammation, which is bad," he said. "Similarly, mutations are happening in the skin all the time. For example, normally, the skin produces an inflammatory factor called IL-12 at a low level to harness the immune system to get rid of mutant cells. When the barrier is broken, IL-12 is diminished, allowing neoplastic cells to proliferate."

As part of the session, Dr. Arbiser reviewed the development of compounds that could target signaling pathways to provide more effective relief for patients. That review included looking at key factors mediating skin barrier regulation and inflammation, including skin acidity, interleukins, nuclear factor kappa B, and sirtuin 3.

Advancing Patient Care in Chronic Spontaneous Urticaria

Online Activity

Reshaping the Future With Targeted Biologic Therapies



PeerView

April W. Armstrong, MD, MPH University of California, Los Angeles (UCLA) Los Angeles, California

CO-CHAIR & PRESENTER

Jason K. Lee, MD, FRCPC, FAAAAI, FACAAI Specialist, Clinical Immunology and Allergy and Internal Medicine Toronto, Ontario, Canada



Watch the Replay

Rubbing elbows



Attendees networked with more than 40 employers at Friday's AAD Career Networking Event at the Marriott Marquis San Diego Marina. The high-energy event gave dermatology job-seekers and soon-to-be graduates the opportunity to network with potential employers and dermatologists from all over the country.



This IME program is provided by PVI, PeerView Institute for Medical Education. This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals This program is independent and is not part of the official AAD Annual Meeting, as planned by its Scientific Assembly Committee. This program does not qualify for AAD continuing medical education (CME) credit.



NOW AVAILABLE!



ZORY/E® (roflumilast) topical foam, 0.3%

DOWN TO AGE 9

Effectively control seborrheic dermatitis and simplify treatment with a steroid-free foam.¹

One foam. Once a day. Anywhere.¹

SebDone.

DRAMATIC 77% IGA SUCCESS AT WEEK 81.2

Trial 203 and STRATUM studies evaluated ZORYVE (n=458) vs vehicle (n=225) once daily for 8 weeks in patients with seborrheic dermatitis. The primary endpoint was IGA Success at Week 8, defined as a score of *Clear* (0) or *Almost Clear* (1) and a \geq 2-grade improvement from baseline. ZORYVE is for topical use only and not for ophthalmic, oral, or intravaginal use.¹

IGA = Investigator Global Assessment

A 2023 Arcutis survey of 93 adults diagnosed with seborrheic dermatitis found that an average of 15 products (including over-the-counter, alternative, and prescription treatments) were reportedly used on a yearly basis.²

INDICATION

Actor portrayal

ZORYVE foam, 0.3%, is indicated for the treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older.

IMPORTANT SAFETY INFORMATION

ZORYVE is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C). **Flammability:** The propellants in ZORYVE are flammable. Avoid fire, flame, and smoking during and immediately following application.

The most common adverse reactions (\geq 1%) include nasopharyngitis (1.5%), nausea (1.3%), and headache (1.1%).

Please see brief summary of full Prescribing Information for ZORYVE foam on the following page.

References: 1. ZORYVE[®] foam. Prescribing information. Arcutis Biotherapeutics, Inc; 2023. **2.** Data on File. Arcutis Biotherapeutics, Inc.

 \odot 2024 Arcutis Biotherapeutics, Inc. All rights reserved. US-COM-154-00125 01/24

See the results at zoryvehcp.com/foam



Brief Summary of Prescribing Information for ZORYVE® (roflumilast) foam, 0.3%, for topical use. See package insert for full Prescribing Information.

INDICATIONS AND USAGE

ZORYVE foam, 0.3%, is indicated for the treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older.

DOSAGE AND ADMINISTRATION

Shake can prior to each use. Apply a thin layer of ZORYVE foam, 0.3%, once daily to affected areas on skin and/or scalp when they are not wet. Rub in completely.

Wash hands after application.

Avoid fire, flame, and smoking during and immediately following application.

ZORYVE foam, 0.3%, is for topical use only and not for ophthalmic, oral, or intravaginal use.

CONTRAINDICATIONS

ZORYVE foam, 0.3%, is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C).

WARNINGS AND PRECAUTIONS

Flammability

The propellants in ZORYVE foam, 0.3%, are flammable. Avoid fire, flame, and smoking during and immediately following application.

ADVERSE REACTIONS

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In two multicenter, randomized, double-blind, vehicle-controlled trials (Trial 203 and STRATUM), 683 adult and pediatric subjects 9 years of age or older with seborrheic dermatitis were treated with ZORYVE foam, 0.3%, or vehicle foam once daily for 8 weeks.

The combined trial population was 79% White, 11% Black, and 5% Asian; for ethnicity, 79% identified as non-Hispanic/Latino and 21% identified as Hispanic/Latino. Fifty percent (50%) were male and 50% were female. The median age was 41 years (range 9 to 87 years). The median body surface area (BSA) affected was 2.5%.

Table 1 presents adverse reactions that occurred in at least 1% of subjects treated with ZORYVE foam, 0.3%.

Table 1. Adverse Reactions Reported in $\geq 1\%$ of Subjects with Seborrheic DermatitisTreated with ZORYVE Foam, 0.3%, for 8 Weeks in Trial 203 and Trial STRATUM

Adverse Reaction	ZORYVE foam, 0.3% (N=458) n (%)	Vehicle foam (N=225) n (%)
Nasopharyngitis	7 (1.5)	1 (0.4)
Nausea	6 (1.3)	0 (0)
Headache	5 (1.1)	0 (0)

The following additional adverse reactions were reported in fewer than 1% of subjects treated with ZORYVE foam, 0.3%: diarrhea and insomnia.

In 408 subjects who continued treatment with ZORYVE foam, 0.3%, for up to 24 to 52 weeks in an open-label, long-term trial, the adverse reaction profile was consistent with that observed in vehicle-controlled trials.

USE IN SPECIFIC POPULATIONS

Pregnancy

<u>Risk Summary</u>

There are insufficient data available on the use of ZORYVE foam, 0.3%, in pregnant women to inform a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. In animal reproduction studies, roflumilast administered orally to pregnant rats and rabbits during the period of organogenesis produced no fetal structural abnormalities at doses up to 30 and 26 times the maximum recommended human dose (MRHD), respectively. Roflumilast induced post-implantation loss in rats at oral doses greater than or equal to 10 times the MRHD. Roflumilast induced stillbirth and decreased pup viability in mice at oral doses 16 and 49 times the MRHD, respectively. Roflumilast has been shown to adversely affect pup post-natal development when dams were treated with an oral dose 49 times the MRHD during pregnancy and lactation periods in mice.

The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations

Labor and delivery

Avoid using ZORYVE foam, 0.3%, during labor and delivery. There are no human studies that have investigated effects of ZORYVE foam, 0.3%, on preterm labor or labor at term; however, animal studies showed that oral roflumilast disrupted the labor and delivery process in mice.

Data Anima

Animal data

In an embryo-fetal development study, pregnant rats were dosed orally during the period of organogenesis with up to 1.8 mg/kg/day roflumilast (30 times the MRHD on a mg/m² basis). No evidence of structural abnormalities or effects on survival rates were observed. Roflumilast did not affect embryo-fetal development at a maternal oral dose of 0.2 mg/kg/day (3 times the MRHD on a mg/m² basis).

In a fertility and embryo-fetal development study, male rats were dosed orally with up to 1.8 mg/kg/day roflumilast for 10 weeks and females for 2 weeks prior to pairing and throughout the organogenesis period. Roflumilast induced pre- and post-implantation loss at maternal oral doses greater than or equal to 0.6 mg/kg/day (10 times the MRHD on a mg/m² basis). Roflumilast did not cause fetal structural abnormalities at maternal oral doses up to 1.8 mg/kg/day (29 times the MRHD on a mg/m² basis).

In an embryo-fetal development study in rabbits, pregnant does were dosed orally with 0.8 mg/kg/day roflumilast during the period of organogenesis. Roflumilast did not cause fetal structural abnormalities at the maternal oral doses of 0.8 mg/kg/day (26 times the MRHD on a mg/m² basis).

In pre- and post-natal developmental studies in mice, dams were dosed orally with up to 12 mg/kg/day roflumilast during the period of organogenesis and lactation. Roflumilast induced stillbirth and decreased pup viability at maternal oral doses greater than 2 mg/kg/day and 6 mg/kg/day, respectively (16 and 49 times the MRHD on a mg/m² basis, respectively). Roflumilast induced delivery retardation in pregnant mice at maternal oral doses greater than 2 mg/kg/day (16 times the MRHD on a mg/m² basis). Roflumilast decreased pup rearing frequencies at a maternal oral dose of 6 mg/kg/day during pregnancy and lactation (49 times the MRHD on a mg/m² basis). Roflumilast also decreased survival and forelimb grip reflex and delayed pinna detachment in mouse pups at a maternal oral dose of 12 mg/kg/day (97 times the MRHD on a mg/m² basis).

Lactation

Risk Summary

There are no data on the presence of roflumilast or its metabolite in human milk, the effects on the breastfed infant, or the effects on milk production.

Roflumilast and/or its metabolites are excreted into the milk of lactating rats. When a drug is present in animal milk, it is likely that the drug will be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for ZORYVE foam, 0.3%, and any potential adverse effects on the breastfeed infant from ZORYVE foam, 0.3%, or from the underlying maternal condition.

Clinical Considerations

To minimize potential exposure to the breastfed infant via breast milk, use ZORYVE foam, 0.3%, on the smallest area of skin and for the shortest duration possible while breastfeeding. To avoid direct infant exposure, advise breastfeeding women not to apply ZORYVE foam, 0.3%, directly to the nipple or areola. If applied to the patient's chest, avoid exposure via direct contact with the infant's skin.

<u>Data</u>

Animal data

Roflumilast and/or its metabolite concentrations measured 8 hours after an oral dose of 1 mg/kg given to lactating rats were 0.32 and 0.02 mcg/g in the milk and pup liver, respectively.

Pediatric Use

The safety and effectiveness of ZORYVE foam, 0.3%, for the treatment of seborrheic dermatitis have been established in pediatric patients 9 years of age and older. Use of ZORYVE foam, 0.3%, in this age group is supported by data from two 8-week, vehicle-controlled trials which included 32 pediatric subjects 9 to 17 years of age, of whom 17 received ZORYVE foam, 0.3%, and from open-label trials of up to 52 weeks which included 23 pediatric subjects treated with ZORYVE foam, 0.3%. The adverse reaction profile was consistent with that observed in adults.

The safety and effectiveness of ZORYVE foam, 0.3%, in pediatric patients below the age of 9 years have not been established.

Geriatric Use

Of the 683 subjects with seborrheic dermatitis exposed to ZORYVE foam, 0.3%, or vehicle for up to 8 weeks in the controlled clinical trials, 98 (14%) were 65 years of age or older, and 33 (5%) were 75 years of age or older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

Hepatic Impairment

Oral roflumilast 250 mcg once daily for 14 days was studied in subjects with hepatic impairment. The systemic exposure of roflumilast and roflumilast N-oxide were increased in subjects with moderate (Child-Pugh B) hepatic impairment. ZORYVE foam, 0.3%, is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C). No dosage adjustment is needed in patients with mild (Child-Pugh A) hepatic impairment.

PATIENT COUNSELING INFORMATION

Advise the patient or caregiver to read the FDA-approved patient labeling (Patient Information). Flammability

Because the propellants in ZORYVE foam, 0.3%, are flammable, instruct the patient to avoid fire, flame, and smoking during and immediately following application.

Lactation

Advise patients to use ZORYVE foam, 0.3%, on the smallest area of skin and for the shortest duration possible while breastfeeding. Instruct patients who are breastfeeding not to apply ZORYVE foam, 0.3%, directly to the nipple or areola to avoid direct infant exposure. Instruct patients to avoid inadvertent contact of treated areas with infant skin.

© 2024 Arcutis Biotherapeutics, Inc. All rights reserved.





Effective. Everywhere. Easy.'

A once-daily, steroid-free cream with the **power to clear elbows and knees**, and the **gentleness for face and folds**.^{1,2}

Actor portrayal

In DERMIS-1 and DERMIS-2, ~40% of patients achieved IGA Success and ~70% of patients achieved I-IGA Success at Week 8.1

ZORYJE (roflumilast) or

DERMIS-1 and DERMIS-2 were identical Phase 3 randomized, parallel, double-blind, vehicle-controlled, multicenter studies that evaluated ZORYVE over 8 weeks as a once-daily, topical treatment for plaque psoriasis. Subjects (N=881) were randomized 2:1 to receive ZORYVE cream 0.3% (n=576) or vehicle (n=305) applied once daily for 8 weeks. Eligibility criteria included a diagnosis of mild, moderate, or severe plaque psoriasis and an affected BSA of 2% to 20%. The primary endpoint was IGA Success at Week 8 and a key secondary endpoint was I-IGA Success at Week 8.¹

IGA Success and I-IGA Success were defined as a score of *Clear* (0) or *Almost Clear* (1) and a \geq 2-grade improvement from baseline.^{1,2}

ZORYVE is for topical use only and not for ophthalmic, oral, or intravaginal use.¹

BSA = Body Surface Area, IGA = Investigator Global Assessment, I-IGA = Intertriginous-IGA

INDICATION

ZORYVE cream is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in patients 6 years of age and older.

IMPORTANT SAFETY INFORMATION

ZORYVE is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C).

The most common adverse reactions (\geq 1%) include diarrhea (3.1%), headache (2.4%), insomnia (1.4%), nausea (1.2%), application site pain (1.0%), upper respiratory tract infection (1.0%), and urinary tract infection (1.0%).

Please see brief summary of full Prescribing Information for ZORYVE cream on the following page.

References: 1. ZORVYE[®] cream. Prescribing information. Arcutis Biotherapeutics, Inc; 2023. **2.** Data on File. Arcutis Biotherapeutics, Inc. See the results at zoryvehcp.com/cream



 \odot 2024 Arcutis Biotherapeutics, Inc. All rights reserved. US-COM-151-00311 01/24

Brief Summary of Prescribing Information for ZORYVE[®] (roflumilast) cream, for topical use. See package insert for full Prescribing Information.

INDICATIONS AND USAGE

ZORYVE cream is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in patients 6 years of age and older.

DOSAGE AND ADMINISTRATION

Apply ZORYVE cream to affected areas once daily and rub in completely. Wash hands after application, unless ZORYVE cream is for treatment of the hands.

ZORYVE cream is for topical use only and not for ophthalmic, oral, or intravaginal use.

CONTRAINDICATIONS

ZORYVE cream is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C).

ADVERSE REACTIONS

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In two multicenter, randomized, double-blind, vehicle-controlled trials (DERMIS-1 and DERMIS-2), 881 adult and pediatric subjects 6 years of age or older with plaque psoriasis were treated with ZORYVE cream or vehicle topically once daily for 8 weeks.

The median age was 47 years (range 6 to 88). The majority of the subjects were male (64%) and White (82%). The median body surface area (BSA) affected was 5.5% (range 2% to 20%). The proportion of subjects who discontinued treatment due to an adverse reaction was 1.0% for subjects treated with ZORYVE cream and 1.3% for subjects treated with vehicle cream. The most common adverse reaction that led to discontinuation of ZORYVE cream was application site urticaria (0.3%).

Table 1 presents adverse reactions that occurred in at least 1% of subjects treated with ZORYVE cream, and for which the rate exceeded the rate for vehicle cream.

Table 1. Adverse Reactions Reported in ${\geq}1\%$ of Subjects with Plaque Psoriasis Treated with ZORYVE Cream (and More Frequently than Vehicle Cream) for 8 Weeks in Trials DERMIS-1 and DERMIS-2

Adverse Reaction	ZORYVE Cream (N=576) n (%)	Vehicle Cream (N=305) n (%)
Diarrhea	18 (3.1)	0 (0.0)
Headache	14 (2.4)	3 (1.0)
Insomnia	8 (1.4)	2 (0.7)
Nausea	7 (1.2)	1 (0.3)
Application site pain	6 (1.0)	1 (0.3)
Upper respiratory tract infection	6 (1.0)	1 (0.3)
Urinary tract infection	6 (1.0)	2 (0.7)

In 594 subjects who continued treatment with ZORYVE cream for up to 64 weeks in openlabel extension trials, the adverse reaction profile was consistent with that observed in vehicle-controlled trials.

USE IN SPECIFIC POPULATIONS

Pregnancy

Risk Summary

There are insufficient data available on the use of ZORYVE cream in pregnant women to inform a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. In animal reproduction studies, roflumilast administered orally to pregnant rats and rabbits during the period of organogenesis produced no fetal structural abnormalities at doses up to 36 and 31 times the maximum recommended human dose (MRHD), respectively. Roflumilast induced post-implantation loss in rats at oral doses greater than or equal to 12 times the MRHD. Roflumilast induced stillbirth and decreased pup viability in mice at oral doses 19 and 59 times the MRHD, respectively. Roflumilast has been shown to adversely affect pup post-natal development when dams were treated with an oral dose 59 times the MRHD during pregnancy and lactation periods in mice.

The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Clinical Considerations

Labor and delivery

Avoid using ZORYVE cream during labor and delivery. There are no human studies that have investigated effects of ZORYVE cream on preterm labor or labor at term; however, animal studies showed that oral roflumilast disrupted the labor and delivery process in mice.

<u>Data</u>

Animal data

In an embryo-fetal development study, pregnant rats were dosed orally during the period of organogenesis with up to 1.8 mg/kg/day roflumilast (36 times the MRHD on a mg/m² basis). No evidence of structural abnormalities or effects on survival rates were observed. Roflumilast did not affect embryo-fetal development at a maternal oral dose of 0.2 mg/kg/day (4 times the MRHD on a mg/m² basis).

In a fertility and embryo-fetal development study, male rats were dosed orally with up to 1.8 mg/kg/day roflumilast for 10 weeks and females for 2 weeks prior to pairing and throughout the organogenesis period. Roflumilast induced pre- and post-implantation loss at maternal oral doses greater than or equal to 0.6 mg/kg/day (12 times the MRHD on a mg/m² basis). Roflumilast did not cause fetal structural abnormalities at maternal oral doses up to 1.8 mg/kg/day (35 times the MRHD on a mg/m² basis).

In an embryo-fetal development study in rabbits, pregnant does were dosed orally with 0.8 mg/kg/day roflumilast during the period of organogenesis. Roflumilast did not cause fetal structural abnormalities at the maternal oral doses of 0.8 mg/kg/day (31 times the MRHD on a mg/m² basis).

In pre- and post-natal developmental studies in mice, dams were dosed orally with up to 12 mg/kg/day roflumilast during the period of organogenesis and lactation. Roflumilast induced stillbirth and decreased pup viability at maternal oral doses greater than 2 mg/kg/day and 6 mg/kg/day, respectively (19 and 59 times the MRHD on a mg/m² basis, respectively). Roflumilast induced delivery retardation in pregnant mice at maternal oral doses greater than 2 mg/kg/day (19 times the MRHD on a mg/m² basis). Roflumilast decreased pup rearing frequencies at a maternal oral dose of 6 mg/kg/day during pregnancy and lactation (59 times the MRHD on a mg/m² basis). Roflumilast also decreased survival and forelimb grip reflex and delayed pinna detachment in mouse pups at a maternal oral dose of 12 mg/kg/day (116 times the MRHD on a mg/m² basis).

Lactation

Risk Summary

There are no data on the presence of roflumilast or its metabolite in human milk, the effects on the breastfed infant, or the effects on milk production.

Roflumilast and/or its metabolites are excreted into the milk of lactating rats. When a drug is present in animal milk, it is likely that the drug will present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for ZORYVE cream and any potential adverse effects on the breastfeed infant from ZORYVE cream or from the underlying maternal condition.

Clinical Considerations

To minimize potential exposure to the breastfed infant via breast milk, use ZORYVE cream on the smallest area of skin and for the shortest duration possible while breastfeeding. To avoid direct infant exposure, advise breastfeeding women not to apply ZORYVE cream directly to the nipple or areola. If applied to the patient's chest, avoid exposure via direct contact with the infant's skin.

<u>Data</u>

Animal data

Roflumilast and/or its metabolite concentrations measured 8 hours after an oral dose of 1 mg/kg given to lactating rats were 0.32 and 0.02 mcg/g in the milk and pup liver, respectively.

Pediatric Use

The safety and effectiveness of ZORYVE cream for the treatment of plaque psoriasis have been established in pediatric patients 6 years of age and older. Use of ZORYVE cream in pediatric patients 6 to less than 18 years of age is supported by data from two 8-week, vehicle-controlled safety and efficacy trials which included 18 pediatric subjects 6 to 17 years of age, of whom 11 received ZORYVE cream. Use of ZORYVE cream in pediatric patients 12 to 17 years of age is also supported by data from open-label trials of 2 and 24 weeks duration which included 18 pediatric subjects 12 to 17 years of age treated with ZORYVE cream. Use of ZORYVE cream in pediatric patients 6 to less than 12 years of age is also supported by data from one 4-week, open-label, safety and pharmacokinetic (PK) study which included 20 pediatric subjects 6 to less than 18 years of age was consistent with that observed in adults.

The safety and effectiveness of ZORYVE cream in pediatric patients below the age of 6 years have not been established.

Geriatric Use

Of the 881 subjects with psoriasis exposed to ZORYVE cream or vehicle for up to 8 weeks in 2 controlled clinical trials, 106 were 65 years of age or older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. Other reported clinical experience has not identified differences in responses between the geriatric and younger patients, but greater sensitivity of some older individuals cannot be ruled out. Based on available data for roflumilast, no adjustment of dosage in geriatric patients is warranted.

Hepatic Impairment

Oral roflumilast 250 mcg once daily for 14 days was studied in subjects with hepatic impairment. The systemic exposure of roflumilast and roflumilast N-oxide were increased in subjects with moderate (Child-Pugh B) hepatic impairment. ZORYVE cream is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C). No dosage adjustment is needed in patients with mild (Child-Pugh A) hepatic impairment.

PATIENT COUNSELING INFORMATION

Advise the patient or caregiver to read the FDA-approved patient labeling (Patient Information). Lactation

Advise patients to use ZORYVE cream on the smallest area of skin and for the shortest duration possible while breastfeeding. Instruct patients who are breastfeeding not to apply ZORYVE cream directly to the nipple and areola to avoid direct infant exposure. Instruct patients to avoid inadvertent contact of treated areas with infant skin.

© 2024 Arcutis Biotherapeutics, Inc. All rights reserved. 01/2024

High-tech hair growth

Non-drug options are flourishing.

echnology to the rescue. Those words may offer hope to countless individuals diagnosed with alopecia. With a rise in emerging technologies for the management of the condition, Saturday's session, U040 – Technological Advancements for the Management of Complex Alopecias, served as the backdrop for a robust discussion of what's new and what's to come.

More than medication

Session director Ronda S. Farah, MD, FAAD, associate professor of dermatology at the University of Minnesota Medical School in Minneapolis, explored the role that certain diverse technologies, such as artificial intelligence (AI), platelet rich plasma (PRP), photobiomodulation (low-level light therapy), hydradermabrasion, hair transplantation, and research in regenerative medicine, play in growing hair and outpacing drug therapy.

"Hair technologies are flourishing. Scalp health is of great interest to consumers and physicians. Dermatologists are taking this to the next level by studying the



From left: Marc R. Avram, MD, FAAD; Ronda S. Farah, MD, FAAD


microbiome," Dr. Farah said. "Also, we are so excited to be working with the industry to launch new hair lasers. In the past, we have worked with photobiomodulation and found in our data that the combs work well in men and women."

Transplant solutions

During the session, Marc R. Avram, MD, FAAD, clinical professor of dermatology at Weill Cornell Medical College in New York, discussed the benefits of hair transplantation. According to Dr. Avram, hair transplantation produces consistently naturalappearing hair for women and men. He credits that to FUT and FUE — two state-of-the-art techniques used to harvest hair from the donor region in the posterior scalp of women and men. During the harvesting consult, the dermatologist will determine which procedure is best. However, both create a natural look, and require a team of skilled surgical assistants.

Additionally, Dr. Avram said long-term medical therapy is important to achieve maximum density from the procedure.

"While a transplant will add density and more hair, it will not stop underlying thinning," he



According to Dr. Avram, hair transplantation can be performed to restore eyebrows as well as repair lost hair from scarring alopecia.

A dream come true

Although most of the session focused on technology, Dr. Farah discussed the integration of oral minoxidil as part of a treatment plan, as it can be beneficial.

"In the last few years our experience with minoxidil has soared. We are excited to share our dosing and starting criteria," she said. "Hair loss medicine and technologies are rapidly evolving. Hair loss is no longer a visit with few tools. It's a visit that the dermatologist will find fulfilling for everyone. We have so much to offer our patients."

Know





Remember to use the American Academy of Dermatology's (AAD) online Continuing Professional Development Transcript (CPD) Program to document your CME and MOC activities to send to a licensing body. This service is a member benefit at no additional fee.*

* Excludes Adjunct and Corporate Individual Members

DermWorld meeting news

President Terrence A. Cronin Jr., MD, FAAD

Physician Reviewer Keyvan Nouri, MD, MBA, FAAD

> Executive Director & CEO Elizabeth K. Usher, MBA Senior VP, Marketing and

Communications Melanie Hall

Director, Communications Katie Domanowski Associate Director, Member

Communications and Publishing Richard Nelson, MS

Senior Manager, Publications Victoria Houghton, MPA

Managing Editor, Special Publications Dean Monti, MFA

> Creative Manager Nicole Torling

Senior Graphic Designer Theresa Oloier

Printed in U.S. ©2024 American Academy of Dermatology |Association 9500 W. Bryn Mawr Ave. Rosemont, IL 60018-5216 Phone (847) 330-0230 Fax (847) 330-0250 www.aad.org

Produced for the American Academy of Dermatology by Ascend Media

After you have read this issue of *DermWorld Meeting News*, please share with colleagues or deposit it in an approved paper recycling bin.

#YourDermatologistKnows the Resource Center is the place to be



The AAD Resource Center (Booth 739) was packed on Friday with members getting free professional headshots, enjoying a nacho bar, mingling with the AAD social media correspondents, and taking fun #YourDermatologistKnows photos for their own social media.

For more information visit www.aad.org/ydk.

UNCOVER SOMETHING DIFFERENT

SHERRI, Real patient

Get the full story about Sherri and other real patients at **Booth 3739.**



© 2024 AbbVie. All rights reserved. US-IMMD-240029



At Eli Lilly and Company, we are making clinically meaningful contributions in the dermatologic community, with a focus on:

- Engaging in impactful research that improves patient care
- Supporting healthcare providers with resources
- Empowering the patient's voice

Explore Skin of Color Medical Resources



